Community statement regarding Biogen and Alcyone collaboration
From SMA Europe we would like to share that Biogen has announced a license and collaboration agreement with the US company, Alcyone Therapeutics, to evaluate further its investigational implantable device called ThecaFlex DRx™.
ThecaFlex DRx offers an alternative means of nusinersen administration for people with SMA.
For the full community statement, please see the attached document.